63086-28-2

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Methoxybenzylamino)acetonitrile is used as a building block for the synthesis of various drugs and pharmaceuticals. Its unique structure allows it to be a key component in the creation of new and innovative medications.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(4-Methoxybenzylamino)acetonitrile serves as an intermediate, particularly in the preparation of biologically active compounds. Its versatility and reactivity make it a valuable asset in the development of new chemical entities.
Used in Medicinal Chemistry:
The presence of the benzylamino group in 2-(4-Methoxybenzylamino)acetonitrile makes it a potentially useful compound in medicinal chemistry. It can be utilized in the design and synthesis of new drugs, targeting specific biological pathways and offering novel therapeutic options.
It is important to handle 2-(4-Methoxybenzylamino)acetonitrile with care, as it may possess toxic and hazardous properties. Proper safety measures should be taken during its use to ensure the well-being of those involved in its synthesis and application.

Upstream product

• 107-14-2 chloroacetonitrile 
• 2393-23-9 4-methoxy-benzylamine 
• 590-17-0 cyanomethyl bromide 
• 50-00-0 formaldehyd 
• 151-50-8 potassium cyanide 

Downstream Products

• 808770-74-3 (E)-N-(p-methoxybenzyl)-C-cyanonitrone 
• 808770-74-3 (Z)-N-(p-methoxybenzyl)-C-cyanonitrone 

Relevant academic research and scientific papers

METHODS OF TREATING COGNITIVE IMPAIRMENT ASSOCIATED WITH NEURODEGENERATIVE DISEASE

Provided herein are methods of treating cognitive impairment associated with neurodegenerative disease in a patient by administering to the patient an effective amount of the Compound, or a pharmaceutically acceptable salt thereof.

SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Cs2CO3-Promoted Direct N-Alkylation: Highly Chemoselective Synthesis of N-Alkylated Benzylamines and Anilines

Herein is described an efficient and chemoselective method for the synthesis of diversely substituted secondary amines in yields up to 98 %. Direct mono-N-alkylation of primary benzylamines and anilines with a wide range of alkyl halides is promoted by a cesium base in the absence of any additive or catalyst. The basicity and solubility of cesium carbonate in anhydrous N,N-dimethylformamide not only enables mono-N-alkylation of primary amines but also suppresses undesired dialkylation of the desired amines.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I : (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and proph

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

The present invention relates to compounds of the formula (I), the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

AKT / PKB INHIBITORS

The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.

Intramolecular Diels-Alder synthesis of 7-aza-α-carboline compounds

An efficient, versatile, and scalable route for the synthesis of 7-aza-α-carboline compounds is described. The tricyclic system has been prepared from modified pyrazinones using a key intramolecular [4+2] Diels-Alder transformation.

Design and synthesis of novel type VI-like β-turn mimetics. Diversity at the i+1 and the i+2 position

In this paper, a synthetic approach for functionalised 5-aminopiperidinone- 2-carboxylate (APC) systems as non-pro cis-peptide bond containing external β-turn mimics is presented. The scope and limitations of the synthetic method are discussed and the pot

A convenient new synthesis of 3-substituted β-lactams formally derived from 1-(aminomethyl)cyclopropanecarboxylic acids

1,3-Dipolar cycloaddition of N-benzyl-C-(methoxycarbonyl)-nitrone (3a), N-benzyl-C-phenylnitrone (3b), N-benzyl-C-cyanonitrone (3c), N-(p-methoxybenzyl)-C-cyanonitrone (3d), N-phenyl- (3e) and N-(2-pyridyl)-C- methylnitrones (3f) to bicyclopropylidene (2)